financetom
Business
financetom
/
Business
/
Under pressure in China, Mercedes trims 2024 car profit outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Under pressure in China, Mercedes trims 2024 car profit outlook
Jul 26, 2024 12:54 AM

July 26 (Reuters) - Mercedes-Benz on Friday

narrowed its annual profit margin forecast for its core car

division as the German luxury automaker faces fierce competition

in China, though new models should lift sales in the second half

of the year.

The company said it now expected an adjusted return on sales

in the range of 10-11% this year, down from its previous target

range of 10-12%.

Mercedes' cars division achieved a 10.2% return on sales in

the second quarter, while its adjusted earnings came in below

analyst expectations.

Mercedes reported a 6% drop in sales in the first half, with

electric vehicle sales falling 17%.

Mercedes said the economic outlook was marked by

uncertainty, adding that it saw improving market sentiment in

Europe and "solid momentum" for sales and demand in the U.S.

market.

The automaker said, however, it had a "cautious view" on

China, where it expected strong competition in its entry-level

and core model segments, while it "seeks to successfully defend

its leading position" of its top-end car models.

"Sales and the model mix are expected to improve in the

second half of the year, supported by further market launches of

new models particularly in the Top-End segment," CEO Ola

Kaellenius said in a statement.

German automakers are struggling with lacklustre demand for

electric vehicles, coupled with tough local competition in

China, supply bottlenecks and persistently high interest rates.

The group reported a 27.5% fall in adjusted earnings in its

car division in the second quarter, against LSEG's estimate of a

26% decline.

At group level, earnings before interest and taxes (EBIT)

dropped in the quarter by 19.1% in line with LSEG's consensus.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved